Daily, Sun 8 Nov: When a better blood marker doesn't help patients
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
This episode covers Akeso's ivonescimab priority review in China, new HORIZON and ZEUS cardiovascular trial details, and earlier Asian research on Kylo-11 and tocilizumab. Plus Allist and Zhifei development steps, AstraZeneca's China infrastructure, vascular devices and Asian egg-bioreactor services.
Full transcript and all sources for this episode
Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Neither Basil nor Ning holds investments in any company mentioned.
Chapters
0:00 Intro and AI-voice disclosure
1:00 Akeso: review versus approval
3:06 China: trial steps and infrastructure
4:41 HORIZON, ZEUS and Eastern context
7:29 Beyond: vascular-device investment
9:07 Beyond: egg-bioreactor tools
11:28 What to watch and Monday sign-off
Key sources: Akeso: priority review · AHA: HORIZON · AHA: ZEUS (all sources on the episode page)
Weekly LinkedIn newsletter
Also listen on: Apple Podcasts · Amazon Music · YouTube
Tell us what you want us to read next, or what we got wrong, in the comments on the weekly LinkedIn newsletter.